Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 14/20 | 0.45 |
| ▸ | CYBB | P04839 | 5/20 | 0.42 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | HTR1B | P28222 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5209635 | 0.79 | NCF1 (0.43) | NCF1CYBBNOX5HTR1DHTR1B | |
| SCHEMBL5213685 | 0.79 | EGFR (0.46) | ALDH1A1 | |
| SCHEMBL31391352 | 0.79 | EGFR (0.46) | ALDH1A1 | |
| SCHEMBL21959294 | 0.72 | TNF (0.46) | — | |
| SCHEMBL7108654 | 0.72 | IDO1 (0.68) | IDO1HTR1DHTR1BALDH1A1 | |
| SCHEMBL30498761 | 0.72 | IDO1 (0.68) | IDO1HTR1DHTR1BALDH1A1 | |
| SCHEMBL5213745 | 0.72 | IDO1 (0.45) | IDO1ALDH1A1 | |
| SCHEMBL4313522 | 0.71 | IDO1 (0.49) | NCF1CYBBNOX5IDO1HTR1D | |
| SCHEMBL8404379 | 0.71 | CYP1A2 (0.42) | ALDH1A1 | |
| SCHEMBL21959267 | 0.70 | TNF (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244726-B2 | Heterocyclic compounds possessing affinity at 5HT1 -type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| US-7214674-B2 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| EP-1480972-B1 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2007-04-11 | — | — | EP | disclosed |
| EP-1476444-B1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| US-20050153974-A1 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| US-20050085458-A1 | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1480974-A1 | HETEROCYCLYLMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| EP-1480972-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004099198-A1 | BENZOXAZINONE DERIVATIVES HAVING AFFINITY FOR 5- HT RECEPTORS, THEIR PREPARATION AND USE | GLAXO GROUP LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
| EP-1476444-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| EP-1476161-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068236-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068760-A2 | COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068772-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003068771-A1 | HETEROCYCLYMETHYLPIPERIDINES AND -PIPERAZINES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | HTR5A, HTR2C, HTR3C | NCF1 2178/4885CYBB 732/4885NOX5 412/4885 |
| US-20050153974-A1 | Heterocyclymethylpiperidines and -piperazines possessing affinity at 5ht-1 type receptors | HTR1A, HTR1D, HTR2C | NCF1 1530/4885CYBB 1451/4885NOX5 1258/4885 |
| US-20050085458-A1 | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy | HTR3C, HTR1A, HTR2C | NCF1 1704/4885CYBB 942/4885NOX5 965/4885 |
| US-20050107410-A1 | Compound possessing affinity at 5ht1-type receptors and use thereof in therapy of cns disorders | CNR1, HTR5A, HTR1A | NCF1 1554/4885CYBB 1335/4885NOX5 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.